上海雅仕投资发展股份有限公司 第四届董事会第十三次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 二、董事会会议审议情况 本次董事会会议审议并通过了以下议案： (一)审议通过《关于增加募投项目实施主体并使用部分募集资金向新增实施主体提供借款以实施募投项 目议案》 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：603329 证券简称：上海雅仕 公告编号：2025-074 一、董事会会议召开情况 上海雅仕投资发展股份有限公司（以下简称"公司"）第四届董事会第十三次会议于2025年11月19日在公 司会议室以现场结合通讯表决方式召开，会议通知及相关资料已于2025年11月14日以电子邮件方式发 出。本次会议应出席会议的董事9名，实际出席会议的董事9名，其中现场参会董事4名，以通讯表决方 式参会董事5名，部分高级管理人员列席会议，本次会议由董事长刘忠义先生主持。会议参与表决人数 及召集、召开程序符合《公司法》和《公司章程》的有关规定，所作决议合法有效。 同意公司新增全资子公司湖北雅仕实业控股有限公司作为募投 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：603329 证券简称：上海雅仕 公告编号：2025-076 上海雅仕投资发展股份有限公司 关于使用募集资金置换已支付发行 费用的自筹资金的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 上海雅仕投资发展股份有限公司（以下简称"公司""上海雅仕"）于2025年11月19日召开第四届董事会第 十三次会议，审议通过了《关于使用募集资金置换已支付发行费用的自筹资金的议案》，同意公司使用 募集资金置换已支付发行费用的自筹资金，置换金额为人民币752,830.19元（不含税），本次募集资金 置换时间距募集资金到账日未超过6个月，符合相关法律法规的规定。现将有关情况公告如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于同意上海雅仕投资发展股份有限公司向特定对象发行股票注册的批 复》（证监许可〔2025〕1825号）同意，公司本次向特定对象发行人民币普通股（A股）43,668,122 股，发行价格6.87元/股，募集资金总额为299,999,998.14元，扣除不含 ...

（文章来源：证券日报） 证券日报网讯 11月19日晚间，上海雅仕发布公告称，公司于2025年11月19日召开第四届董事会第十三 次会议，审议通过了《关于使用募集资金置换已支付发行费用的自筹资金的议案》，同意公司使用募集 资金置换已支付发行费用的自筹资金，置换金额为人民币752，830.19元（不含税），本次募集资金置 换时间距募集资金到账日未超过6个月。 ...

证券日报网讯 11月19日晚间，上海雅仕发布公告称，公司于2025年11月19日召开第四届董事会第十三 次会议，审议通过了《关于增加募投项目实施主体并使用部分募集资金向新增实施主体提供借款以实施 募投项目的议案》，同意公司新增全资子公司湖北雅仕实业控股有限公司（简称"湖北雅仕"）作为募投 项目实施主体并开立募集资金专项账户，与公司共同实施"补充流动资金或偿还银行贷款项目"，并使用 部分募集资金向新增实施主体提供借款以实施募投项目。 （文章来源：证券日报） ...

上海雅仕投资发展股份有限公司（证券代码：603329，证券简称：上海雅仕）于2025年11月20日发布公 告称，公司第四届董事会第十三次会议已于11月19日审议通过《关于使用部分闲置募集资金进行现金管 理的议案》，同意公司及子公司使用不超过2亿元（含本数）的闲置募集资金进行现金管理，投资期限 为自董事会审议通过之日起十二个月，资金可在上述额度及有效期内循环滚动使用。 本次议案无需提交公司股东大会审议，董事会已授权董事长及其授权人士在额度范围内行使投资决策权 并签署相关文件，财务部门将负责具体组织实施。 点击查看公告原文>> 声明：市场有风险，投资需谨慎。 本文为AI大模型基于第三方数据库自动发布，任何在本文出现的信 息（包括但不限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成 个人投资建议。受限于第三方数据库质量等问题，我们无法对数据的真实性及完整性进行分辨或核验， 因此本文内容可能出现不准确、不完整、误导性的内容或信息，具体以公司公告为准。如有疑问，请联 系biz@staff.sina.com.cn。 责任编辑：小浪快报 据公告披露，本次现金管理的投资品种将聚焦安全性高、流动性 ...

Group 1 - Kanglongda's shareholder plans to reduce holdings by up to 3% of the company's shares, totaling no more than 4.83 million shares [1] - The company specializes in the research, production, and sales of special and ordinary labor protection gloves [1] Group 2 - Haizheng Pharmaceutical's subsidiary plans to collaborate with East China Institute on a biological method for synthesizing heparin, with a project contract amount not exceeding 120 million yuan [2] - The company focuses on the research, production, and sales of chemical raw materials and formulations [3] Group 3 - Tianyin Holdings received approval from the China Securities Regulatory Commission for a stock issuance to specific investors [4] - The company is engaged in the sales of smart terminals, e-commerce, lottery, mobile resale, and mobile internet businesses [4] Group 4 - Shanghai Yashi plans to use up to 200 million yuan of temporarily idle raised funds for cash management in high-security, liquid deposit products [5] - The company specializes in supply chain logistics and execution trade [6] Group 5 - Parker New Materials intends to use 130 million yuan of idle raised funds to purchase structured deposits with expected annual yields between 0.59% and 2.9001% [7] - The company focuses on the research, production, and sales of various types of ring forgings, free forgings, and die forgings [7] Group 6 - Huayang New Materials appointed Jing Hongsheng as the new general manager [8] Group 7 - Liyuan Technology's shareholder plans to reduce holdings by up to 2.03% of the company's shares, totaling no more than 3.04 million shares [9] - The company specializes in the research, design, and integration of environmental water treatment systems and hydrogen fuel cell engine systems [9] Group 8 - Shengnuo Biopharmaceutical's subsidiary received approval for the listing application of Visepegenatide raw materials, a GLP-1 receptor agonist for treating type 2 diabetes and obesity [10][11] - The company focuses on the research, production, and sales of peptide raw materials and formulations [10] Group 9 - Puluo Pharmaceutical plans to repurchase shares worth between 180 million and 360 million yuan, with a maximum price of 23 yuan per share [12] - The company specializes in the research, production, and sales of raw material intermediates and innovative drugs [12] Group 10 - Dongfang Electric's subsidiary plans to establish a joint venture with Anhui Waneng Energy, with a registered capital of approximately 1.857 billion yuan [13] - The company is involved in the development, design, manufacturing, and sales of advanced power generation equipment [13] Group 11 - Hefei China announced that its stock will resume trading on November 20 after completing a review of abnormal trading fluctuations [14] - The company focuses on international trade and after-sales services related to in vitro diagnostic medical devices [14] Group 12 - Dafeng Industrial won a bid for the stage equipment project of the Shenzhen International Performing Arts Center, with a contract amount of 165 million yuan [15] - The company specializes in cultural sports equipment, digital art technology, and operation services [15] Group 13 - Baiyunshan's subsidiary received a drug registration certificate for An Gong Niu Huang Wan in Vietnam [16] - The company is engaged in the research, manufacturing, and sales of traditional Chinese and Western medicines [16] Group 14 - Neusoft Group received a notification to supply intelligent cockpit domain controllers for multiple models from a well-known domestic automobile manufacturer, with an estimated total amount of about 4.2 billion yuan [17] - The company focuses on providing industry solutions and software products [17] Group 15 - Huayu Pharmaceutical's product received overseas marketing approval [18] - The company specializes in the research, production, and sales of innovative and high-quality generic drugs in the oncology field [18] Group 16 - Yao Pi Glass received approval from the CSRC for its stock issuance to specific investors [19] - The company specializes in the production and sales of float glass and processed glass [19] Group 17 - Guangyu Yuan's vice president Wang Junbo resigned due to work adjustments [20] - The company focuses on the production and sales of traditional Chinese medicine products [20] Group 18 - Biyi Co. received approval from the CSRC for its stock issuance to specific investors [21] - The company specializes in the design, manufacturing, and sales of smart small household appliances [21] Group 19 - Sunshine Nuohe's application for acquiring 100% equity of Jiangsu Langyan Life Science Technology Co., Ltd. through share issuance and convertible bonds has been accepted by the Shanghai Stock Exchange [22] - The company provides comprehensive drug research and development services for domestic pharmaceutical enterprises and research institutions [22] Group 20 - Longxin General plans to increase capital in its wholly-owned subsidiary by no more than 1.65 billion yuan [23] - The company specializes in the research, production, and sales of motorcycles and engines [23] Group 21 - Jiekang Equipment received a corrective order from the Tianjin Securities Regulatory Bureau due to internal control deficiencies [24] - The company specializes in the research, production, and sales of nuclear biochemical safety equipment [24] Group 22 - Wantong Technology plans to raise no more than 920 million yuan through a private placement to supplement working capital [25] - The company focuses on information technology services for highways and ports [25] Group 23 - Dongshan Precision has submitted an application for H-share listing to the Hong Kong Stock Exchange [26] - The company specializes in the research, production, and sales of electronic circuit products and precision components [26] Group 24 - Yonghe Intelligent Control plans to publicly transfer 100% equity of its wholly-owned subsidiary Kunming Medical Oncology Hospital [27] - The company specializes in water and heating valve fittings, tumor precision radiation therapy, and photovoltaic battery businesses [27] Group 25 - Aok Shares signed a strategic cooperation framework agreement with Suzhou Qitian New Materials Co., Ltd. [28] - The company focuses on the research and production of high-end new materials derived from ethylene oxide and ethylene [28] Group 26 - Hongquan Technology's shareholder plans to reduce holdings by up to 3% of the company's shares, totaling no more than 299,440 shares [29] - The company specializes in the research, production, and sales of intelligent connected products and software platform development [29] Group 27 - Shilong Industrial's controlling shareholder plans to reduce holdings by up to 3% of the company's shares, totaling no more than 7.2 million shares [30] - The company specializes in the research, production, and sales of chemical products [30] Group 28 - Tangrenshen decided to terminate the investment in the "Dongchong Phase III Pig Breeding Base Construction Project," reallocating the remaining funds of 78.9587 million yuan to supplement working capital [31] - The company specializes in the research, production, and sales of feed, pigs, meat products, and animal health products [31] Group 29 - Gaode Infrared's actual controller plans to reduce holdings by up to 3% of the company's shares, totaling no more than 12.8 million shares [32] - The company specializes in infrared focal plane detector chips and infrared thermal imaging systems [32] Group 30 - Kangyuan Pharmaceutical's actual controller recently increased holdings by 20,000 shares [33] - The company specializes in the research, production, and sales of pharmaceuticals [33] Group 31 - Haida Group plans to repurchase shares worth between 1 billion and 1.6 billion yuan, with a maximum price of 62.00 yuan per share [34] - The company provides overall solutions for animal husbandry [34] Group 32 - Qizhong Technology's 850 million yuan convertible bonds have been approved for listing [35] - The company specializes in advanced packaging and testing of integrated circuits [35] Group 33 - Dingyang Technology launched the new SNA5000B series vector network analyzer [36] - The company specializes in the research, production, and sales of general electronic testing and measuring instruments [36] Group 34 - Airo Energy plans to distribute a cash dividend of 0.9375 yuan per share to all shareholders [37] - The company specializes in photovoltaic energy storage systems and products [37] Group 35 - Hechuan Technology's actual controller and some directors plan to reduce holdings by up to 6% of the company's shares [38] - The company specializes in the research, production, and sales of industrial automation products [38] Group 36 - China First Heavy Industries' chairman was arrested for suspected bribery [39] - The company specializes in heavy machinery manufacturing for various industries [39] Group 37 - Lianhuan Pharmaceutical plans to invest 15 million yuan in joint research with Nanjing University for anti-thrombotic small nucleic acid drugs [40] - The company specializes in the manufacturing and sales of chemical raw materials [40] Group 38 - Anxu Biotech's shareholder plans to reduce holdings by up to 0.94% of the company's shares, totaling no more than 120,000 shares [41] - The company specializes in the research, production, and sales of POCT reagents and instruments [41] Group 39 - Yaxiang Integration's shareholder reduced holdings by 130,000 shares [42] - The company specializes in providing cleanroom engineering and related services for high-tech electronic industries [42] Group 40 - Zhongwen Media plans to use up to 9.5 billion yuan of idle funds to purchase financial products [43] - The company specializes in traditional publishing and various new media businesses [43]

截至发稿，上海雅仕市值为30亿元。 每经头条（nbdtoutiao）——爱泼斯坦案文件解密倒计时，美国会"秒过"法案直通特朗普，引爆两党"极 限撕扯" （记者 张明双） 每经AI快讯，上海雅仕（SH 603329，收盘价：12.19元）11月19日晚间发布公告称，公司第四届第十三 次董事会会议于2025年11月19日在公司会议室以现场结合通讯表决方式召开。会议审议了《关于变更注 册资本并修订 <公司章程> 的议案》等文件。 2025年1至6月份，上海雅仕的营业收入构成为：供应链执行贸易占比73.44%，多式联运占比18.1%，第 三方物流服务占比7.87%，其他业务占比0.59%。 ...

向新增实施主体提供借款以实施募投项目的核查意见 国联民生证券承销保荐有限公司（以下简称"保荐机构"）作为上海雅仕投 资发展股份有限公司（以下简称"上海雅仕"或"公司"）2024 年度向特定对象 发行 A 股股票的保荐机构，根据《证券发行上市保荐业务管理办法》《上市公司 募集资金监管规则》《上海证券交易所股票上市规则》《上海证券交易所上市公司 自律监管指引第 1 号——规范运作》等有关规定，对上海雅仕增加募投项目实施 主体并使用部分募集资金向新增实施主体提供借款以实施募投项目事项进行了 审慎核查。核查的情况及核查意见如下： 国联民生证券承销保荐有限公司 关于上海雅仕投资发展股份有限公司 增加募投项目实施主体并使用部分募集资金 一、募集资金基本情况 （一）募集资金情况 经中国证券监督管理委员会《关于同意上海雅仕投资发展股份有限公司向特 定对象发行股票注册的批复》（证监许可〔2025〕1825 号）同意，公司本次向特 定对象发行人民币普通股（A 股）43,668,122 股，发行价格 6.87 元/股，募集资金 总额为 299,999,998.14 元，扣除不含税发行费用人民币 2,775,158.61 元，募集资 ...

国联民生证券承销保荐有限公司 关于上海雅仕投资发展股份有限公司 使用部分闲置募集资金进行现金管理的核查意见 国联民生证券承销保荐有限公司（以下简称"保荐机构"）作为上海雅仕投 资发展股份有限公司（以下简称"上海雅仕"或"公司"）2024 年度向特定对象 发行 A 股股票的保荐机构，根据《证券发行上市保荐业务管理办法》《上市公司 募集资金监管规则》《上海证券交易所股票上市规则》《上海证券交易所上市公司 自律监管指引第 1 号——规范运作》等有关法律法规的规定，对上海雅仕使用部 分闲置募集资金进行现金管理事项进行了审慎核查。核查的情况及核查意见如 下： 一、投资情况概述 （一）投资目的 为提高上海雅仕募集资金使用效率，在不影响募集资金使用和公司正常经营 的情况下，公司将合理利用暂时闲置募集资金进行现金管理，增加资金收益，为 公司及股东获取投资回报。本次现金管理不会影响公司主营业务的发展，本次资 金使用安排合理。 （二）投资金额及期限 公司及子公司拟使用不超过 20,000 万元（含本数）的闲置募集资金进行现 金管理，有效期为自公司董事会审议通过之日起十二个月内有效。在上述额度及 有效期内，资金可循环滚动使用，期限 ...

国联民生证券承销保荐有限公司 关于上海雅仕投资发展股份有限公司 使用募集资金置换已支付发行费用的自筹资金的核查意见 国联民生证券承销保荐有限公司（以下简称"保荐机构"）作为上海雅仕投 资发展股份有限公司（以下简称"上海雅仕"或"公司"）2024 年度向特定对象 发行 A 股股票的保荐机构，根据《证券发行上市保荐业务管理办法》《上市公司 募集资金监管规则》《上海证券交易所股票上市规则》《上海证券交易所上市公司 自律监管指引第 1 号——规范运作》等有关法律法规的规定，对上海雅仕使用募 集资金置换已支付发行费用的自筹资金事项进行了审慎核查。核查的情况及核查 意见如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于同意上海雅仕投资发展股份有限公司向特 定对象发行股票注册的批复》（证监许可〔2025〕1825 号）同意，公司本次向特 定对象发行人民币普通股（A 股）43,668,122 股，发行价格 6.87 元/股，募集资 金总额为 299,999,998.14 元，扣除不含税发行费用人民币 2,775,158.61 元，募集 资金净额为人民币 297,224,839.53 元。立信会计师事务所（特殊普通合 ...